Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

Most academic precision oncology programs have been designed to facilitate enrollment of patients in early clinical trials with matched targeted agents. Over the last decade, major changes were seen both in the targetable molecular alteration landscape and in drug development trends. In this article...

Descripción completa

Detalles Bibliográficos
Autores principales: Dienstmann, Rodrigo, Garralda, Elena, Aguilar, Susana, Sala, Gemma, Viaplana, Cristina, Ruiz-Pace, Fiorella, González-Zorelle, Jenifer, Grazia LoGiacco, Deborah, Ogbah, Zighereda, Ramos Masdeu, Laia, Mancuso, Francesco, Fasani, Roberta, Jimenez, Jose, Martinez, Paola, Oaknin, Ana, Saura, Cristina, Oliveira, Mafalda, Balmaña, Judith, Carles, Joan, Macarulla, Teresa, Elez, Elena, Alsina, Maria, Braña, Irene, Felip, Enriqueta, Tabernero, Josep, Rodon, Jordi, Nuciforo, Paolo, Vivancos, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Special Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446427/
https://www.ncbi.nlm.nih.gov/pubmed/32923891
http://dx.doi.org/10.1200/PO.19.00398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446427/
https://www.ncbi.nlm.nih.gov/pubmed/32923891
http://dx.doi.org/10.1200/PO.19.00398

Ejemplares similares